We are focused on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need.

Our technology

The unique potential of Radiopharmaceuticals in treating oncological diseases.

Learn more

Our pipeline

The unique potential of being First to Market or Best in Class.

Learn more

Our team

We have a unique commitment to improve patients’ hope in fighting cancer.

Learn more

Information for investors

Stock price, Company governance & updates from our multiple development programs.

Learn more

Latest news

ASX Releases

Dr. Rama Abu Shmeis appointed Senior VP, CMC

January 11, 2023

Read moreRead more

ASX Releases

avB6 Integrin (RAD301) IND Approval for Phase 1 Trial

December 29, 2022

Read moreRead more

ASX Releases

RAD201 HER2 Nanobody Demonstrates Favourable Tumor Targeting

December 13, 2022

Read moreRead more